Follow Us:
Nefopam

Acupan

Nefopam

Nefopam is a centrally acting, non-opioid analgesic used for the relief of moderate acute pain, including postoperative, dental, and musculoskeletal pain. It works by modulating pain-processing pathways in the central nervous system, partly through inhibition of serotonin, noradrenaline, and dopamine reuptake.

Dosage Form:
Dosage Strength:
CAS No.: 13669-70-0
Status:
Manufacturer:
Group: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Sub Group: Antipyretic Drugs
Class: Benzoxazocine Derivatives

Uses of Nefopam

Nefopam was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

  • Analgesic Research: Certain derivatives have been studied for their potential to reduce moderate to severe pain through opioid receptor interactions.
  • Opioid Receptor Research: These compounds are used in pharmacological investigations to understand opioid receptor activity and related signalling pathways.
  • Central Nervous System Research: Selected derivatives have been investigated for their effects on neurological and behavioural processes.
  • Pain Management Research: Some compounds have been explored as potential alternatives or modifications to existing opioid analgesics.
  • Medicinal Chemistry Research: Benzoxazocine structures provide a framework for developing and studying compounds with different receptor-binding properties.

Contraindication of Nefopam

Nefopam was historically subject to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Known hypersensitivity to the active compound or formulation ingredients.
  • Severe respiratory depression, particularly for opioid-active derivatives.
  • Acute or severe bronchial asthma in an inadequately monitored setting, where the compound carries opioid-related respiratory risks.
  • Concurrent use with certain central nervous system depressants when the combination presents an unacceptable risk.
  • Severe hepatic or renal impairment where safe administration cannot be established.
  • Pregnancy or breastfeeding where the specific compound has established safety restrictions.
  • Conditions associated with an increased risk of opioid-related complications, depending on the individual medicine.

Precautions for Nefopam

Nefopam was majorly subjected to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Central Nervous System Effects: Compounds with opioid receptor activity may cause drowsiness, dizziness, sedation and impaired coordination.
  • Respiratory Function: Opioid-active derivatives may suppress breathing, particularly at higher exposures or when combined with other central nervous system depressants.
  • Dependence and Misuse: Certain opioid-active compounds may carry risks of tolerance, physical dependence and misuse.
  • Liver and Kidney Function: Patients with hepatic or renal impairment may require additional assessment because drug metabolism and elimination can be affected.
  • Cardiovascular Effects: Some compounds may affect blood pressure or heart rate, depending on their pharmacological activity.
  • Pregnancy and Breastfeeding: Safety information varies between compounds. Opioid-active derivatives may present risks to the fetus or newborn.
  • Elderly Patients: Older adults may be more susceptible to sedation, falls and respiratory complications.
  • Driving and Machinery: Patients should avoid activities requiring alertness if the compound causes sedation or impaired coordination.

Drug Interactions for Nefopam

Potential drug interactions were historically documented when Nefopam was prescribed alongside certain medications. These included:

  • Benzodiazepines: Diazepam, alprazolam and other benzodiazepines may increase sedation and respiratory depression when combined with opioid-active compounds.
  • Alcohol: Alcohol may intensify drowsiness, impaired coordination and respiratory suppression.
  • Other Opioids: Concurrent use may increase the risk of excessive sedation and respiratory depression.
  • Sedative Medicines: Sleeping tablets, sedating antihistamines and other central nervous system depressants may increase adverse effects.
  • Antidepressants: Certain combinations may increase central nervous system adverse effects or, depending on the compound, cause additional pharmacological interactions.
  • Antipsychotics: Concurrent administration may increase sedation and impairment.
  • CYP Enzyme Modifiers: Medicines that inhibit or induce drug-metabolising enzymes may alter the exposure of certain derivatives.

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Nefopam.

The Nefopam hydrochloride is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Nefopam.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Nefopam, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Nefopam Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Nefopam

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Nefopam Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Nefopam, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Nefopam

The export of Nefopam from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Nefopam Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Nefopam specifications, certificates of analysis, and other supporting documents required for Nefopam export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Nefopam export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Nefopam regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Nefopam documentation, labelling, Nefopam manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Nefopam Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Nefopam, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.